To produce antibodies capable of neutralizing botulinum neurotoxin type A (BoNT/A), the murine humoral immune response to BoNT/A binding domain (H C ) was characterized at the molecular level by using phage antibody libraries. Mice were immunized with BoNT/A H C , the spleens were harvested, and single-chain Fv (scFv) phage antibody libraries were constructed from the immunoglobulin heavy and light chain variable region genes. Phage expressing BoNT/A binding scFv were isolated by selection on immobilized BoNT/A and BoNT/A H C . Twenty-eight unique BoNT/A H C binding scFv were identified by enzyme-linked immunosorbent assay and DNA sequencing. Epitope mapping using surface plasmon resonance in a BIAcore revealed that the 28 scFv bound to only 4 nonoverlapping epitopes with equilibrium constants (K d ) ranging from 7.3 ؋ 10 ؊8 to 1.1 ؋ 10 ؊9 M. In a mouse hemidiaphragm assay, scFv binding epitopes 1 and 2 significantly prolonged the time to neuroparalysis, 1.5-and 2.7-fold, respectively, compared to toxin control. scFv binding to epitopes 3 and 4 showed no protection against neuroparalysis. A combination of scFv binding epitopes 1 and 2 had an additive effect on time to neuroparalysis, which increased to 3.9-fold compared to the control. The results suggest that there are two "productive" receptor binding sites on H C which lead to toxin internalization and toxicity. Blockade of these two epitopes with monoclonal antibodies may provide effective immunoprophylaxis or therapy against BoNT/A intoxication.
Botulism is a life-threatening flaccid paralysis caused by a neurotoxin produced by the anaerobic bacterium Clostridium botulinum. The disease typically results from ingestion of preformed toxin present in contaminated food (15) or from toxin produced in vivo from infected wounds (50) or in the intestines of infants (2) (or occasionally adults). In severe cases, patients require prolonged hospitalization in an intensive-care unit and mechanical ventilation. Specific therapy consists of administration of botulism antitoxin trivalent (equine) (48) ; however, this product has a high incidence of side effects, including serum sickness and anaphylaxis (5) . To avoid these side effects, human BIG has been produced from immunized volunteers and its efficacy is being determined in a prospective randomized trial in infants with botulism (1) . While theoretically nontoxic, human BIG also has limitations, largely related to production issues. These include potential transmission of blood-borne infectious diseases, variability in potency and specificity between lots, and the need to immunize humans. The latter issue has taken on increased importance with the use of BoNTs for the treatment of a range of neuromuscular diseases (28, 41) . Immunization of volunteers for production of BIG would deprive them of subsequent botulinum therapy.
As an alternative to immune globulin, neutralizing monoclonal antibodies with defined potency and specificity could be produced in unlimited quantities. To date, however, no efficacious neutralizing antibotulinum monoclonal antibodies have been produced (38) . Potential explanations for this failure include the following: (i) a neutralizing epitope(s) is less immunogenic than other epitopes; (ii) too few unique monoclonal antibodies have been studied; (iii) a toxoid immunogen (formaldehyde-inactivated crude toxin) which poorly mimics the conformation of the neutralizing epitope(s) has been used; and (iv) multiple epitopes must be blocked in order to achieve efficient neutralization (32) . To address these issues, and to generate neutralizing antibodies to BoNT/A, we have produced and characterized a large panel of monoclonal antibodies from immunized mice. To generate antibodies capable of preventing the binding of toxin to its cellular receptor(s), mice were immunized with BoNT/A H C (33) . This domain contains the region(s) thought to bind to presynaptic neuronal receptors, the first requisite step for intoxication, and results in protective immunity when used as an immunogen (11, 33) . To produce and characterize the greatest number of monoclonal antibodies possible, we used phage display (10, 37 ; reviewed in reference 34). Murine V H and V genes were used to construct libraries of millions of recombinant scFv, which were displayed on the surface of filamentous bacteriophage (Fig. 1) . Phage displaying antibodies binding BoNT/A were isolated by affinity chromatography. Here we report the molecular and biophysical characterization of these antibodies, including specificity, affinity, epitopes recognized, and in vitro neutralization capacity. Oligonucleotide design. Family-specific murine V H and V primers were designed as previously described for human V-gene primers (35, 36) to amplify full-length rearranged V genes. Briefly, murine V H and V DNA sequences were collected from the Kabat et al. (30) and GenBank databases, aligned, and classified by family, and family-specific primers were designed to anneal to the first 23 nucleotides comprising framework 1. Similarly, J H and J gene-segmentspecific primers were designed to anneal to the final 24 nucleotides comprising each of the 4 J H and 5 J gene segments (30) .
Vector construction. To construct the vector pSYN3, a 1.5-kb stuffer fragment was amplified from pCANTAB5E (Pharmacia Biotech, Milwaukee, Wis.) by using PCR and the primers LMB3 (35) and E-tagback (5Ј-ACCACCGAATTCT TATTAATGGTGATGATGGTGGATGACCAGCCGGTTCCAGCGG-3Ј). The DNA fragment was digested with SfiI and NotI, gel purified, and ligated into pCANTAB5E digested with SfiI and NotI. Ligated DNA was used to transform Escherichia coli TG1 (19) , and clones containing the correct insert were identified by DNA sequencing. The resulting vector permits subcloning of phagedisplayed scFv as SfiI-NotI or NcoI-NotI fragments for secretion into the periplasm of E. coli as native scFv with a C-terminal E epitope tag followed by a hexahistidine tag.
Immunizations. For construction of library 1, BALB/c mice (16 to 22 g) were immunized at 0, 2, and 4 weeks with pure BoNT/A H C (Ophidian Pharmaceuticals, Madison, Wis.). Each animal was given subcutaneously 1 g of material adsorbed onto alum (Pierce Chemical Co., Rockford, Ill.) in a volume of 0.5 ml. Mice were challenged 2 weeks after the second immunization with 100,000 50% lethal doses of pure BoNT/A and were sacrificed 1 week later. For construction of library 2, CD-1 mice (16 to 22 g) were immunized at 0, 2, and 4 weeks with pure BoNT/A H C and were sacrificed 2 weeks after the third immunization. For both libraries, the spleens were removed immediately after sacrifice and total RNA was extracted by the method of Cathala et al. (7) .
Library construction. First-strand cDNA was synthesized from approximately 10 g of total RNA exactly as previously described (35) , except that immunoglobulin mRNA was specifically primed with 10 pmol each of MIgG1 For, MIgG3 For, and MC For (Table 1) . For construction of library 1, rearranged V H and V genes were amplified from first-strand cDNA by using commercially available V H and V back primers and J H and J forward primers (Recombinant Phage Antibody System; Pharmacia Biotech). For library 2, equimolar mixtures of family-specific V H and V back primers were used in conjunction with equimolar mixtures of J H or J gene-segment-specific forward primers in an attempt to increase library diversity (see "Oligonucleotide design" above). Rearranged V H and V genes were amplified separately in 50-l reaction mixtures containing 5 l of the first-strand cDNA reaction mixture, 20 pmol of an equimolar mixture of the appropriate back primers, 20 pmol of an equimolar mixture of the appropriate forward primers, 250 M (each) deoxynucleoside triphosphate, 1.5 mM MgCl 2 , 10 g of bovine serum albumin/ml, and 1 l (5 U) of Thermus aquaticus (Taq) DNA polymerase (Promega) in the buffer supplied by the manufacturer. The reaction mixture was overlaid with paraffin oil (Sigma) and cycled 30 times (at 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min). Reaction products were gel purified, isolated from the gel by using DEAE membranes, eluted from the membranes with high-salt buffer, ethanol precipitated, and resuspended in 20 l of water (43) . scFv gene repertoires were assembled from purified V H and V gene repertoires and linker DNA by using splicing by overlap extension. Linker DNA encoded the peptide sequence (G 4 S) 3 (27) and was complementary to the 3Ј ends of the rearranged V H genes and the 5Ј ends of the rearranged V genes. The V H and V DNAs (1.5 g of each) were combined with 500 ng of linker DNA (Recombinant Phage Antibody System; Pharmacia Biotech) in a 25-l PCR mixture containing 250 M (each) deoxynucleoside triphosphate, 1.5 mM MgCl 2 , 10 g of bovine serum albumin/ml, and 1 l (5 U) of Taq DNA polymerase (Promega) in the buffer supplied by the manufacturer, and the mixture was cycled 10 times (at 94°C for 1 min, 62°C for 1 min, and 72°C for 1 min) to join the fragments. Flanking oligonucleotide primers (RS, provided in the Recombinant Phage Antibody System kit, for library 1 and an equimolar mixture of V H Sfi and J Not primers [ Table 1 ] for library 2) were added, and the reaction mixture was cycled for 33 cycles (at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min) to append restriction sites. scFv gene repertoires were gel purified as described above, digested with SfiI and NotI, and purified by electroelution, and 1 g of each repertoire was ligated into either 1 g of pCANTAB5E vector (Pharmacia Biotech) (library 1) or 1 g of pHEN-1 (25) (library 2) digested with SfiI and NotI. The ligation mix was purified by extraction with phenol-chloroform, ethanol precipitated, and resuspended in 20 l of water, and 2.5-l samples were electroporated (16) into 50 l of E. coli TG1 (19) . Cells were grown in 1 ml of SOC (43) for 30 min and then plated on TYE (39) medium containing 100 g of AMP/ml and 1% (wt/vol) GLU (TYE-AMP-GLU). Colonies were scraped off the plates into 5 ml of 2ϫ TY broth (39) containing 100 g of AMP/ml, 1% GLU (2ϫ TY-AMP-GLU), and 15% (vol/vol) glycerol for storage at Ϫ70°C. The cloning efficiency and diversity of the libraries were determined by PCR screening (20) exactly as described in reference 36.
Preparation of phage. To rescue phagemid particles from the libraries, 10 ml of 2ϫ TY-AMP-GLU was inoculated with an appropriate volume of bacteria (approximately 50 to 100 l) from the library stocks to give an A 600 of 0.3 to 0.5 and bacteria were grown for 30 min with shaking at 37°C. About 10 12 PFU of VCS-M13 (Stratagene) particles were added, and the mixture was incubated at FIG. 1. Strategy for in vitro antibody production using phage display libraries. mRNA is prepared from splenocytes, first-strand cDNA is prepared, and antibody V H and V L genes are amplified by PCR. V H and V L genes are spliced together randomly by using PCR to create a repertoire of scFv genes. The scFv gene repertoire is cloned into a phagemid vector in frame with a gene (gIII) encoding a phagemid minor coat protein (pIII). Each phage in the resulting phage antibody library expresses an scFv-pIII fusion protein on its surface and contains the gene encoding the scFv inside. Phage antibodies binding a specific antigen can be separated from nonbinding phage antibodies by affinity chromatography on immobilized antigen. A single round of selection increases the number of antigen-binding phage antibodies by a factor ranging from 20 to 10,000, depending on the affinity of the antibody. Eluted phage antibodies are used to infect E. coli, which then produces more phage antibodies for the next round of selection. Repeated rounds of selection make it possible to isolate antigen-binding phage antibodies that were originally present at frequencies of less than one in a billion.
37°C for 30 min without shaking, followed by incubation at 37°C for 30 min with shaking. Cells were spun down, resuspended in 50 ml of 2ϫ TY broth containing 100 g of AMP/ml and 50 g of KAN/ml (2ϫ TY-AMP-KAN), and grown overnight with shaking at 25°C. Phage particles were purified and concentrated by two polyethylene glycol precipitations (43) , resuspended in 5 ml of PBS, and filtered through a 0.45-m-pore-size filter. The phage preparation consistently resulted in a titer of approximately 10 13 TU of AMP-resistant clones/ml. Selection of phage antibody libraries. Both libraries were selected by using 75-by 12-mm immunotubes (Maxisorp; Nunc) coated with 1 ml of BoNT/A (50 g/ml; kindly provided by Ray Stevens) or BoNT/A H C (10 g/ml) in PBS 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAT GTG CAG CTT CAG GAG TCR GG 3Ј V H 3 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTG CAG CTG AAG SAG TCA GG 3Ј V H 4/6 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTY CAG CTG CAR CAR TCT GG 3Ј V H 5/9 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTY CAR CTG CAG CAG YCT GG 3Ј V H 7 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAR GTG AAG CTG GTG GAR TCT GG 3Ј V H 8 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTT CAG CTT CAG CAG TCT GG 3Ј V H 10 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAA GTG CAG CTG KTG GAG WCT GG 3Ј V H 11 Sfi 5Ј GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG ATC CAG TTG CTG CAG TCT GG 3Ј 
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overnight at 4°C. Tubes were blocked for 1 h at 37°C with 2% MPBS, and selection, washing, and elution were performed exactly as described in reference 35 by using phage at a concentration of 5.0 ϫ 10 12 TU/ml. One-third of the eluted phage was used to infect 10 ml of log-phase E. coli TG1, which was plated on TYE-AMP-GLU plates as described above. The rescue-selection-plating cycle was repeated three times, after which clones were analyzed for binding by ELISA. Libraries were also selected on soluble BoNT/A H C . For library 1, 1.0 mg of BoNT/A H C (700 g/ml) was biotinylated (Recombinant Phage Selection Module; Pharmacia) and purified as recommended by the manufacturer. For each round of selection, 1 ml of phage (approximately 10 13 TU) were mixed with 1 ml of PBS containing 4% skim milk powder, 0.05% Tween 20, and 10 g of biotinylated BoNT/A H C /ml. After 1 h at room temperature, antigen-bound phage were captured on blocked streptavidin-coated M280 magnetic beads (Dynabeads; Dynal) exactly as described in reference 45. Dynabeads were washed a total of 10 times (three times in TPBS, twice in TMPBS, twice in PBS, once in MPBS, and two more times in PBS). Bound phage were eluted from the Dynabeads by incubation with 100 l of 100 mM triethylamine for 5 min and were neutralized with 1 M Tris-HCl, pH 7.5, and one-third of the eluate was used to infect log-phase E. coli TG1. For library 2, affinity-driven selections (22, 45) were performed by decreasing the concentration of soluble BoNT/A H C used for selection (10 g/ml for round 1, 1 g/ml for round 2, and 10 ng/ml for round 3). Soluble BoNT/A H C was captured on 200 l of Ni 2ϩ -NTA (Qiagen) via a C-terminal hexahistidine tag. After capture, the Ni 2ϩ -NTA resin was washed a total of 10 times (5 times in TPBS and 5 times in PBS), bound phage were eluted as described above, and the eluate was used to infect log-phase E. coli TG1.
Initial characterization of binders. Initial analysis for binding to BoNT/A, BoNT/A H C , and BoNT/A H N (kindly provided by Ray Stevens) (8) was performed by ELISA using bacterial supernatant containing expressed scFv. Expression of scFv (13) was performed in 96-well microtiter plates exactly as described in reference 35. For ELISA, microtiter plates (Falcon 3912) were coated overnight at 4°C with either BoNT/A, BoNT/A H C , or BoNT/A H N (10 g/ml) in PBS and then were blocked with 2% MPBS for 1 h at room temperature. Bacterial supernatants containing expressed scFv were added to wells and incubated at room temperature for 1.5 h. Plates were washed six times (3 times with TPBS and 3 times with PBS), and binding of scFv was detected via their C-terminal peptide tags (E epitope tag for library 1 in pCANTAB5E and myc epitope tag [42] for library 2 in pHEN-1) by using either anti-myc tag antibody (9E10; Santa Cruz Biotechnology) or anti-E antibody (Pharmacia Biotech) and peroxidase-conjugated anti-mouse Fc antibody (Sigma), as described in references 35 and 44. The number of unique binding scFv was determined by BstN1 fingerprinting and DNA sequencing.
Subcloning, expression, and purification of scFv. To facilitate purification, scFv genes were subcloned into the expression vector pUC119mycHis (46) or pSYN3, resulting in the addition of a hexahistidine tag at the C-terminal end of the scFv. Two-hundred-milliliter cultures of E. coli TG1 harboring one of the appropriate phagemids were grown, expression of scFv was induced with IPTG (13) , and the cultures were grown at 25°C overnight. scFv was harvested from the periplasm (6) , dialyzed overnight at 4°C against IMAC loading buffer (50 mM sodium phosphate [pH 7.5], 500 mM NaCl, 20 mM imidazole), and then filtered through a 0.2-m-pore-size filter. scFv was purified by IMAC (24) exactly as described in reference 46. To separate monomeric scFv from dimeric and aggregated scFv, samples were concentrated to a volume of Ͻ1 ml in a centrifugal concentrator (Centricon 10; Amicon) and fractionated on a Superdex 75 column (Pharmacia) by using HBS. The purity of the final preparation was evaluated by assaying an aliquot by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein bands were detected by Coomassie blue staining. The concentration was determined spectrophotometrically, on the assumption that an A 280 of 1.0 corresponds to an scFv concentration of 0.7 mg/ml.
Measurement of affinity and binding kinetics. The K d s of purified scFv were determined by using surface plasmon resonance in a BIAcore (Pharmacia Biosensor AB). In a BIAcore flow cell, approximately 600 RU of BoNT/A H C (15 g/ml in 10 mM sodium acetate [pH 4.5]) was coupled to a CM5 sensor chip by using N-hydroxysuccinimide-N-ethyl-NЈ-(dimethylaminopropyl)carbodiimide chemistry (29) . This amount of coupled BoNT/A H C resulted in a maximum RU of 100 to 175 of scFv bound. For regeneration of the surface after binding of scFv, 5 l of 4 M MgCl 2 was injected, resulting in a return to baseline. The surface was reused 20 to 30 times under these regeneration conditions. Association was measured under a continuous flow of 5 l/min with a concentration range from 50 to 1,000 nM. k on was determined from a plot of ln (dR/dt)/t versus concentration, where R is response and t is time (31) . k off was determined from the dissociation part of the sensorgram at the highest concentration of scFv analyzed (31) by using a flow rate of 30 l/min. K d was calculated as k off /k on .
Epitope mapping. Epitope mapping was performed by using surface plasmon resonance in a BIAcore. In a BIAcore flow cell, approximately 1,200 RU of BoNT/A H C was coupled to a CM5 sensor chip as described above. With a flow rate of 5 l/min, a titration of 100 nM to 1 M scFv was injected over the flow cell surface for 5 min to determine an scFv concentration which resulted in near saturation of the surface. Epitope mapping was performed with pairs of scFv at concentrations resulting in near saturation and at least 100 RU of scFv bound. The amount of scFv bound was determined for each member of a pair, and then the two scFv were mixed together to give a final concentration equal to the concentration used for measurements of the individual scFv. scFv recognizing different epitopes showed an additive increase in the RU bound when injected together ( Fig. 2A) , while scFv recognizing identical epitopes showed only a minimal increase in RU (Fig. 2B) .
In vitro neutralization studies. In vitro neutralization studies were performed by using a mouse hemidiaphragm preparation, as described by Deshpande et al. (14) . Briefly, left and right phrenic nerve hemidiaphragm preparations were excised from male CD/1 mice (25 to 33 g) and suspended in physiological solution (135 mM NaCl, 5 mM KCl, 15 mM NaHCO 3 , 1 mM Na 2 HPO 4 , 1 mM MgCl 2 , 2 mM CaCl 2 , and 11 mM GLU). The incubation bath was bubbled with 95% O 2 -5% CO 2 and maintained at a constant temperature of 36°C. Phrenic nerves were stimulated supramaximally at 0.05 Hz with square waves of 0.2 ms duration. Isometric twitch tension was measured with a force displacement transducer (Model FT03; Grass) connected to a chart recorder. Purified scFv were incubated with purified BoNT/A for 30 min at room temperature and then added to the tissue bath, resulting in a final scFv concentration of 2.0 ϫ 10 Ϫ8 M and a final BoNT/A concentration of 2.0 ϫ 10 Ϫ11 M. For each scFv studied, time to 50% twitch tension reduction was determined three times for BoNT/A alone and three times for scFv plus BoNT/A. The combination of S25 and C25 was studied at a final concentration of 2.0 ϫ 10 Ϫ8 M each. Differences between times to 50% twitch reduction were determined by a two-tailed t test, with a P value of Ͻ0.05 considered significant.
FIG. 2.
Sensorgrams illustrating technique used to epitope map scFv binding to BoNT/A H C . Epitope mapping was performed by using surface plasmon resonance in a BIAcore, with scFv studied in pairs. Each scFv was injected into the BIAcore and allowed to bind to BoNT/A H C coupled to the sensor chip surface until saturation was achieved. The amount (in RU) bound for each scFv alone was compared to the amount bound when the two scFv were mixed and injected together. Point a, baseline, followed by the beginning of injection; points b 1 
RESULTS

Phage antibody library construction and characterization.
Two phage antibody libraries were constructed from the V H and V genes of immunized mice (Fig. 1) . For library 1, a mouse was immunized twice with BoNT/A H C and challenged 2 weeks after the second immunization with 100,000 50% lethal doses of BoNT/A. The mouse survived the BoNT/A challenge and was sacrificed 1 week later. The spleen was removed immediately after sacrifice, and total RNA was prepared. For library construction, IgG heavy-chain and kappa light-chain mRNA were specifically primed and first-strand cDNA was synthesized. V H and V gene repertoires were amplified by PCR, and V H , J H , V , and J primers were provided in the recombinant phage antibody system. The V H and V gene repertoires were randomly spliced together to create an scFv gene repertoire by using synthetic DNA encoding the 15-amino-acid peptide linker (G 4 S) 3 . Each scFv gene repertoire was separately cloned into the phage display vector pCANTAB5E (Pharmacia). After transformation, a library of 2.1 ϫ 10 6 members was obtained. Ninety percent of the clones had an insert of the appropriate size for an scFv gene, as determined by PCR screening, and the cloned scFv genes were diverse, as determined by PCR fingerprinting (data not shown). DNA sequencing of 10 unselected clones from library 1 revealed that all V H genes were derived from the murine V H 2 family and all V genes were derived from the murine V 4 and V 6 families (30). Based on this observed V-gene bias, family-specific V H and V primers were designed along with J H and J genesegment-specific primers (Table 1) . These primers were then used to construct a second phage antibody library. For library 2, a mouse was immunized three times with BoNT/A H C and sacrificed 2 weeks after the third immunization. The mouse was not challenged with BoNT/A prior to spleen harvest, as this led to the production of non-H C -binding antibodies (see "Selection and initial characterization of phage antibodies" below). The spleen was harvested, and a phage antibody library was constructed as described above, except that V H -, J H -, V -, and J -specific primers were used. After transformation, a library of 1.0 ϫ 10 6 members was obtained. Ninety-five percent of the clones had an insert of the appropriate size for an scFv gene, as determined by PCR screening, and the cloned scFv genes were diverse, as determined by PCR fingerprinting (data not shown). DNA sequencing of 10 unselected clones from library 2 revealed greater diversity than was observed in library 1; V H genes were derived from the V H 1, V H 2, and V H 3 families, and V genes were derived from the V 2, V 3, V 4, and V 6 families (30).
Selection and initial characterization of phage antibodies. To isolate BoNT/A binding phage antibodies, phage were rescued from the library and selected on either purified BoNT/A or BoNT/A H C . Selections were performed on the holotoxin in addition to H C , since it was unclear to what extent the recombinant toxin H C would mimic the conformation of the H C in the holotoxin. Selection for BoNT/A and BoNT/A H C binders was performed on antigen adsorbed to polystyrene. In addition, H C binding phage were selected in solution on biotinylated H C , with capture on streptavidin magnetic beads (for library 1) or on hexahistidine tagged H C , with capture on Ni 2ϩ -NTA agarose (for library 2). Selections in solution were utilized based on our previous observation that selection on protein adsorbed to polystyrene could yield phage antibodies which did not recognize native protein (46) . Selection in solution was not performed on the holotoxin due to our inability to successfully biotinylate the toxin without destroying immunoreactivity.
After two to three rounds of selection, at least 67% of scFv analyzed bound the antigen used for selection ( Table 2 ). The number of unique scFv was determined by DNA fingerprinting followed by DNA sequencing, and the specificity of each scFv was determined by ELISA on pure BoNT/A and recombinant BoNT/A H C and H N . scFv binding BoNT/A but not binding H C or H N were presumed to bind the light chain (catalytic domain). A total of 33 unique scFv were isolated from mice immunized with H C and challenged with BoNT/A ( Table 3 , library 1). When library 1 was selected on holotoxin, 25 unique scFv were identified. Only 2 of these scFv, however, bound H C , with the majority (21) binding the light chain and 2 binding H N . The two H C binding scFv did not express as well as other scFv recognizing similar epitopes, and they were therefore not characterized with respect to affinity or neutralization capacity (see below). Selection of library 1 on H C yielded an additional eight unique scFv (Tables 3 and 4) . Overall, however, only 50% of scFv selected on H C also bound holotoxin. This result suggests that a significant portion of the H C surface may be inaccessible in the holotoxin. Alternatively, scFv could be binding H C conformations that do not exist in the holotoxin. From mice immunized with H C only (library 2), all scFv selected on holotoxin also bound H C . As with library 1, however, only 50% of scFv selected on H C bound holotoxin. In all, 18 unique H C binding scFv were isolated from library 2, resulting in a total of 28 unique H C binding scFv (Tables 3 and 4) . scFv of identical 
Full-length sequences were not determined for clones C12, C13, C2, and S44 (all bind epitope 1). Accession can be made through GenBank with nos. AF003702 to AF003725.
or related sequences were isolated on both H C immobilized on polystyrene and H C in solution. Thus, in the case of H C , the method of selection was not important. Epitope mapping. All 28 unique H C binding scFv were epitope mapped by using surface plasmon resonance in a BIAcore. Epitope mapping was performed with pairs of scFv at concentrations resulting in near saturation of the chip surface and at least 100 RU of scFv bound. The amount of scFv bound was determined for each member of a pair, and then the two scFv were mixed together to give a final concentration equal to the concentration used for measurements of the individual scFv. scFv recognizing different epitopes showed an additive increase in the RU bound when injected together ( Fig. 2A) , while scFv recognizing identical epitopes showed only a minimal increase in RU (Fig. 2B) . By this technique, mapping of the 28 scFv yielded 4 nonoverlapping epitopes recognized on H C (Table 4) . scFv recognizing only epitopes 1 and 2 were obtained from library 1, whereas scFv recognizing all 4 epitopes were obtained from library 2. Many of the scFv recognizing the same epitope (C1 and S25; C9 and C15; 1E8 and 1G7; 1B6 and 1C9; C25 and C39; 2G5, 3C3, 3F4, and 3H4; 1A1 and 1F1; 1B3 and 1C6; 1G5 and 1H6; 1F3 and 2E8) had V H domains derived from the same V-D-J rearrangement, as evidenced by the high level of homology of the V H CDR3 and V H -gene segment (Table 4) . These scFv differ only by substitutions introduced by somatic hypermutation or PCR error. For epitopes 1 and 2, most or all of the scFv recognizing the same epitope are derived from the same or very similar V Hgene segments but differ significantly with respect to V H CDR3 length and sequence (5 of 9 scFv for epitope 1; 8 of 8 scFv for epitope 2) ( Table 4 ). These include scFv derived from different mice. Given the great degree of diversity in V H CDR2 sequences in the primary repertoire (49), specific V H -gene segments may have evolved for their ability to form binding sites capable of recognizing specific pathogenic antigenic shapes. In contrast, greater structural variation appears to occur in the rearranged V genes. For example, three different germ line genes and CDR1 main-chain conformations (9) are observed for epitope 2, where all the V H genes are derived from the same germ line gene. Such "promiscuity" in chain pairings has been reported previously (10) .
Affinity, binding kinetics, and in vitro toxin neutralization. Affinity, binding kinetics, and in vitro toxin neutralization were determined for one representative scFv binding to each epitope. For each epitope, the scFv chosen for further study had the best combination of high expression level and slow k off , as determined during epitope mapping studies. K d for the four scFv studied ranged between 7.3 ϫ 10 Ϫ8 and 1.1 ϫ 10 Ϫ9 M (Table 5 ), values comparable to those reported for monoclonal IgG produced from hybridomas (18) . C25 has the highest affinity (K d ϭ 1.1 ϫ 10 Ϫ9 M) reported for an anti-botulinum toxin antibody. k on differed over 84-fold, and k off differed over 33-fold, between scFv (Table 5 ). In vitro toxin neutralization was determined by using a mouse hemidiaphragm preparation and measuring the time to 50% twitch tension reduction for BoNT/A alone and in the presence of 2.0 ϫ 10 Ϫ8 M scFv. Values are reported in time to 50% twitch reduction. scFv binding to epitope 1 (S25) and epitope 2 (C25) significantly prolonged the time to neuroparalysis: 1.5-fold (152%) and 2.7-fold (270%), respectively (Table 5 and Fig. 3 ). In contrast, scFv binding to epitopes 3 and 4 had no significant effect on the time to neuroparalysis. A mixture of S25 and C25 had a significant additive effect on the time to neuroparalysis, with the time to 50% twitch reduction increasing 3.9-fold (390%).
DISCUSSION
BoNTs consist of a heavy and a light chain linked by a single disulfide bond. The carboxy-terminal half of the toxin binds to a specific membrane receptor(s), resulting in internalization, while the amino-terminal half mediates translocation of the toxin from the endosome into the cytosol. The light chain is a zinc endopeptidase which cleaves an essential synaptosomal protein, leading to failure of synaptic transmission and paralysis. Effective immunotherapy must prevent binding of the toxin to the receptor, since the other two toxin functions occur intracellularly. Identification of epitopes on H C which mediate binding is an essential first step, both to the design of better vaccines and to development of a high-titer neutralizing monoclonal antibody (or antibodies) for passive immunotherapy.
For this work, we attempted to direct the immune response to a neutralizing epitope(s) by immunization with recombinant BoNT/A H C . This should lead to the production of antibodies which prevent binding of toxin to its cellular receptor(s). One limitation of this approach is the extent to which recombinant H C mimics the conformation of H C in the holotoxin. The fact that 50% of antibodies selected on H C recognize holotoxin suggests significant structural homology for a large portion of the molecule. Although 50% of antibodies selected on H C do not bind holotoxin, this could result from packing of a significant portion of the H C surface against other toxin domains. Our results do not, however, exclude the possibility that some of these antibodies are binding H C conformations that do not exist in the holotoxin or that conformational epitopes present in the holotoxin are absent from recombinant H C . This could lead to failure to generate antibodies to certain conformational epitopes. Regardless, immunizing and selecting with H C resulted in the isolation of a large panel of monoclonal antibodies which bind holotoxin. In contrast, monoclonal antibodies isolated after immunization with holotoxin or toxoid bind to other toxin domains (H N or light chain) or to nontoxin proteins present in crude toxin preparations and toxoid (results from library 1, this work and reference 17).
To produce and characterize the greatest number of monoclonal antibodies possible, we used phage display. This approach makes it possible to create and screen millions of different antibodies for binding. The resulting antibody fragments are already cloned and can easily be sequenced to identify the number of unique antibodies. Expression levels in E. coli are typically adequate to produce milligram quantities of scFv, which can easily be purified by IMAC after subcloning into a vector which attaches a hexahistidine tag to the C terminus. Ultimately, the V H and V L genes can be subcloned to construct complete IgG molecules, grafted to construct humanized antibodies, or mutated to create ultrahigh-affinity antibodies. By this approach, 28 unique monoclonal anti-BoNT/A H C antibodies were produced and characterized. The antibody sequences were diverse, consisting of 3 different V H -gene families, at least 13 unique V-D-J rearrangements, and 3 V -gene families. Generation of this large panel of BoNT/A H C antibodies was a result of the choice of antigen used for immunization and selection (BoNT/A H C ). For example, a Fab phage antibody library constructed from the V genes of mice immunized with pentavalent toxoid yielded only two Fab which bound pure toxin (in this case, BoNT/B). The majority of the Fab bound nontoxin proteins present in the toxoid (17) . Despite the sequence diversity of the antibodies, epitope mapping revealed only four nonoverlapping epitopes. Epitopes 1 and 2 were immunodominant, being recognized by 21 of 28 (75%) of the antibodies. Interestingly, approximately the same number (three to five) of immunodominant BoNT/A H C peptide (nonconformational) epitopes are recognized by mouse and human polyclonal antibodies after immunization with pentavalent toxoid and by horse polyclonal antibodies after immunization with formaldehyde-inactivated BoNT/A (3). scFv binding epitopes 1 and 2 resulted in partial antagonism of toxin-induced neuroparalysis at the mouse neuromuscular junction. When administered together, the two scFv had an additive effect, with the time to neuroparalysis increasing significantly. These results are consistent with the presence of two unique receptor binding sites on BoNT/A H C . While the BoNT/A receptor(s) has not been formally identified, the results are consistent with those of ligand binding studies, which also indicate two classes of receptor binding sites on toxin, high and low affinity, and have led to a "dual receptor" model for toxin binding (40) . Whether both of these sites are on H C , however, is controversial. In two studies, BoNT/A H C partially inhibited binding and neuromuscular paralysis (4, 5) , whereas Daniels-Holgate and Dolly (12) showed that BoNT/A H C inhibited binding at motor nerve terminals but had no antagonistic effect on toxin-induced neuroparalysis at the mouse neuromuscular junction. Our results are consistent with the presence of two "productive" receptor binding sites on H C which result in toxin internalization and toxicity. Differences in scFv potency may reflect differences in affinity of H C for receptor binding sites or may reflect the greater than 10-fold difference in affinity of scFv for H C . Finally, we have not formally shown that any of the scFv actually block binding of toxin to the cell surface. It is conceivable that the observed effect on time to neuroparalysis results from interference with a postbinding event.
scFv antagonism of toxin-induced neuroparalysis in the mouse hemidiaphragm assay was less than that (7.5-fold prolongation of time to neuroparalysis) observed for 2.0 ϫ 10 Ϫ9 M polyclonal equine antitoxin (PerImmune Inc.) (47a). This difference could be due to the necessity of blocking additional binding sites, differences in antibody affinity or avidity, or a cross-linking effect leading to aggregated toxin which cannot bind. Affinity of antibody binding is also likely to be an important factor, since the toxin binds with high affinity to its receptor (51) and can be concentrated inside the cell by internalization. Of note, the most potent scFv has the highest affinity for H C . Availability of other scFv described here, which recognize the same neutralizing epitope but with different K d s, should help define the importance of affinity. These scFv, however, differ by many amino acids and may also differ in fine specificity, making interpretation of results difficult. Alternatively, mutagenesis combined with phage display can lead to the production of scFv which differ by only a few amino acids in sequence but vary by several orders of magnitude in affinity (47) . The same approach can be used to increase antibody affinity into the picomolar range (47) .
The "gold standard" for neutralization is protection of mice against the lethal effects of toxin coinjected with antibody. While the relationship between in vitro and in vivo protection has not been formally established, equine antitoxin potentially neutralizes toxin in both types of assays (see above and reference 21). Presumably, this relationship holds for the scFv reported here, but this will need to be verified experimentally. Such studies are not possible with small (25-kDa) scFv antibody fragments. The small size of scFv leads to rapid redistribution (the half-life at ␣ phase is 2.4 to 12 min) and clearance (the half-life at ␤ phase is 1.5 to 4 h) and antibody levels which rapidly become undetectable (26, 46) , while toxin levels presumably remain high (23) . Performance of in vivo studies will require the construction of complete IgG molecules from the V H and V L genes of scFv. Use of human constant regions will yield chimeric antibodies less immunogenic than murine monoclonals and much less immunogenic than currently used equine antitoxin. Immunogenicity could be further reduced by CDR grafting to yield humanized antibodies.
